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Introduction
Germline mutations in RECQL4 are found in the majority of Roth-
mund-Thomson syndrome (RTS) patients (OMIM 268400) (1–5). 
RTS is a rare autosomal recessive disorder that presents with epi-
thelial features (skin atrophy, hyper/hypopigmentation), congenital 
skeletal malformations (leading to short stature), premature aging, 
and an increased incidence of cancer, including osteosarcoma and 
hematological malignancy (4–6). RTS patients can present with 
multiple malignancies and are more susceptible to chemotherapy-
induced malignancy (7, 8). Mutations in RECQL4 also associate with 
2 additional syndromes, Rapadilino and Baller-Gerold syndrome 
(BGS), that share varying degrees of overlap in their clinical manifes-
tation with RTS (6, 9). The in vivo functions of RECQL4 in mamma-
lian systems have remained unclear. A better understanding of the 
functions of RECQL4 is likely to provide important insight into the 
diseases associated with RECQL4 mutation in humans.
RECQL4 is 1 of 5 human DNA helicases that have evolved from 
prokaryote recQ+ (9, 10). Similar to RECQL4, the related Werner 
(WRN) or Bloom (BLM) syndrome helicases are associated with 
familial cancer predisposition and aging syndromes. RECQL4 has 
been demonstrated to act as an ATP-dependent DNA helicase and 
to play a role in maintaining genome stability (11). In contrast to 
other RecQ helicases, RECQL4 displays additional homology in 
its N-terminal region to yeast Sld2 and may thereby participate in 
the initiation of DNA replication (12–18). The relative importance 
of the RecQ helicase function of RECQL4 compared with its role 
in DNA replication has not been ascertained. Mutations associated 
with RTS predominantly affect the helicase function and are largely 
absent from the N-terminal Sld2-like region of RECQL4 (1–5).
Murine models have revealed stark differences in survival de-
pending on the region of Recql4 targeted. Missense mutations or hy-
pomorphic Recql4 alleles are viable, whereas an N-terminal targeted 
allele was embryonic lethal very early (19–21). To bypass embryonic 
lethality, we generated the first conditional allele of Recql4 and in-
vestigated the role of RECQL4 upon widespread somatic deletion 
in the adult mouse. Recql4Δ/Δ mice developed acute BM failure, with 
progression to hematopoietic failure. There was evidence of highly 
elevated levels of cell death in vivo. The B cell and T cell lineage de-
fects could be recapitulated in vitro, demonstrating a cell intrinsic 
requirement for RECQL4. Loss of RECQL4 caused an increase in 
DNA damage and an accumulation of cells in the S-phase of the cell 
cycle, most consistent with a DNA replication failure. Strikingly, and 
in agreement with this interpretation, hematopoietic colony forma-
tion and B and T cell differentiation could be fully rescued by a RecQ 
helicase inactive mutated RECQL4. Collectively, these data identify 
RECQL4 as a unique regulator of hematopoiesis that has functions 
distinct from other RecQ helicases in the regulation of hematopoiesis.
Results
Generation of Recql4fl/fl mice. We generated a conditional allele of 
Recql4 by inserting loxP sites on either side of exons 9 and 10 (Rec-
ql4fl/fl) that encodes the start of the RecQ helicase domain, the lo-
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phenotyping (Figure 2, D and E, and refs. 24, 25). When the expres-
sion pattern of Recql4 transcript was assessed in the Gene Expression 
Commons database, the most severely impacted lineages in Recql4Δ/Δ 
displayed a striking and specific overlap with the points of highest 
transcript expression (Supplemental Figure 2 and ref. 26). Splenic 
erythropoiesis was significantly decreased (Supplemental Figure 3). 
Thymic lymphopoiesis was reduced, and T cell progenitors were se-
verely impaired. All of the CD4+ and CD8+ cell populations in the BM 
of Recql4Δ/Δ were TCRβ positive, indicating recirculating mature cells 
(Supplemental Figure 3). Due to the rapid BM failure, we assessed 
whether there were changes in apoptosis. Immunohistochemical 
analysis revealed an approximately 2.5-fold increase in cleaved cas-
pase-3–positive cells in the BM of the Recql4Δ/Δ, suggesting that the 
rapid BM failure may be due to elevated apoptosis (Figure 2F).
To determine whether BM failure was due to stem cell 
and/or progenitor depletion, we assessed these populations 
using multiple phenotypic approaches (27–30). Surprisingly, 
the phenotypic long- and short-term HSC numbers per femur 
were relatively unaffected by loss of Recql4 (Figure 3, A and C). 
However, there were significant changes in the myelo-erythroid 
progenitor populations. Granulocyte-macrophage progenitors 
(GMPs) and common myeloid progenitors (CMPs) were main-
tained at the expense of the megakaryocyte-erythroid progeni-
tor (MEP) (Figure 3B). A higher fidelity analysis of the erythroid 
progenitors demonstrated substantially compromised pools of 
pre-MegE and CFU-Es (Figure 3, D and E). Colony forming cell 
assays demonstrated approximately 60% reduction in progeni-
tors in Recql4Δ/Δ BM (Supplemental Figure 4). These data dem-
onstrate that loss of RECQL4 leads to a rapid-onset, multilin-
eage BM failure, demonstrating an essential requirement for 
RECQL4 in the maintenance of hematopoiesis.
Increased cell death of early progenitors and mature cells. To better 
understand the mechanism for the BM failure, we analyzed tamox-
ifen-treated R26-CreERki/+Recql4+/+, R26-CreERki/+Recql4fl/+, and 
R26-CreERki/+Recql4fl/fl cohorts at earlier time points, before they 
displayed any clinical disease (14 days; Figure 4A). The PB and BM 
phenotypes were similar to those seen after 30 days of tamoxifen, al-
beit less severe (Table 2 and Figure 4, B–G). Using annexinV/7AAD 
staining, we found increased proportions of dead cells (annexinV+/–
7AAD+) in the Recql4Δ/Δ BM, most pronounced in the multipotent 
progenitor (MPP) (Figure 4H), committed progenitor fractions (Fig-
ure 4, I and J), and erythroid populations (Figure 4K and Supple-
mental Table 1). Thus, the selective death of progenitor populations 
leads to the observed BM failure. There were significantly elevated 
levels of DNA damage in the Recql4Δ/Δ BM and thymus as assessed 
by γH2A.X staining, a marker of DNA breaks (Figure 5, A–C). In ad-
dition, increased intracellular cleaved caspase-3 was apparent in 
thymocytes in vivo (Figure 5C), correlating with the decreased thy-
mus cellularity. These results demonstrate that deletion of Recql4 
causes the elimination of proliferative progenitor cells through in-
creased DNA damage and ultimately apoptosis.
RECQL4 is essential for HSCs to repopulate hematopoiesis. R26-
CreER mediates deletion of Recql4 in many cell types, including he-
matopoietic cells. To ascertain whether the BM failure was reflective 
of a hematopoietic cell–intrinsic role for RECQL4, we performed a 
series of BM transplants and employed an additional HSC-specific 
Cre strain (31–34). Competitive transplantation of BM derived from 
cation of the majority of mutations in RTS patients (refs. 5, 6, and 
Supplemental Figure 1, A–C; supplemental material available online 
with this article; doi:10.1172/JCI75334DS1). Homozygous Recql4fl/fl 
mice were viable and fertile and displayed no phenotype. This al-
lele was efficiently excised on Cre expression, resulting in a loss of 
detectable protein (Supplemental Figure 1, D and E). Recql4+/– mice 
were normal and fertile, with no apparent basal phenotype or aging-
induced phenotypes. Intercrosses of Recql4+/– did not yield any vi-
able Recql4–/– pups at weaning. Analysis of embryos as early as E10.5 
did not recover any viable Recql4–/– embryos. This early embryonic 
lethality of germline loss of RECQL4 is consistent with the previ-
ously reported germline N-terminal targeted allele (Table 1).
Widespread somatic deletion of Recql4 results in BM failure. We 
crossed the Recql4fl/fl allele to the Rosa26-CreERT2 (R26-CreER; ref. 
22) line to allow tamoxifen-induced somatic deletion across a broad 
range of tissues. At 7 weeks of age, cohorts of R26-CreERki/+Recql4+/+, 
R26-CreERki/+Recql4fl/+, and R26-CreERki/+Recql4fl/fl were fed 
tamoxifen containing chow for up to 30 days. This resulted in ef-
ficient recombination of the genomic locus in the BM (Figure 1A). 
Within approximately 3 weeks, R26-CreERki/+Recql4fl/fl (Recql4Δ/Δ) 
began to display signs of illness, most notably weight loss and pale 
tail tips and feet (Figure 1A and data not shown). Within 4 weeks, 
all Recql4Δ/Δ displayed this phenotype, with no effect on the R26-
CreERki/+Recql4+/+ and R26-CreERki/+Recql4fl/+ controls.
Analysis of the peripheral blood (PB) revealed severe multilin-
eage cytopenias in Recql4Δ/Δ (Figure 1, B–G). Effects were observed 
across all lineages with myeloid, B lymphoid, and T lymphoid cell 
numbers severely reduced. Surprisingly, we observed no change in 
platelet numbers in the PB (Figure 1D). Accompanying the PB cy-
topenias, Recql4Δ/Δ mice displayed profound red cell aplasia in the 
setting of a moderately hypocellular BM (Figure 1, H and I). Con-
sistent with the normal platelet count in the PB, megakaryocyte 
numbers were not reduced in the BM. The BM architecture was 
grossly disorganized, and there were distinctive changes in the 
BM microenvironment. There was an accumulation of adipocytes, 
known to impair hematopoietic support and often accompanying 
BM failure (Figure 1I and ref. 23). Autopsy did not reveal any gross 
pathology of other organs. All together, the Recql4Δ/Δ mice had BM 
failure with a relative sparing of the megakaryocyte lineage.
Closer examination of the BM of Recql4Δ/Δ animals revealed an 
approximately 70% decrease in BM cellularity (Figure 2A). Myeloid 
output was reduced and there were defects in B lymphoid develop-
ment, predominantly at the transition from pre-proB to proB stages 
(Figure 2, B and C). BM erythropoiesis was reduced, with the most 
marked reductions occurring in the earliest nucleated erythroid pop-
ulations as assessed by either CD71/Ter119 or Ter119/CD44/FSC 
Table 1. Data from breeding of Recql4+/– intercrosses
Age (dpc) Genotype
Litters +/+ +/– –/– Total
E10.5 3 7 23 1A 31
E14.5 3 9 11 0 20
Weaning 27 62 118 0 180
AFound dead.
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To directly address the hematopoietic-intrinsic role of REC-
QL4, we transplanted nondeleted fetal liver or adult BM from R26-
CreERki/+Recql4+/+, R26-CreERki/+Recql4fl/+, and R26-CreERki/+Recql4fl/fl 
into congenic recipients. After 4 to 6 weeks of recovery, chimerism 
was assessed, and then the recipients were placed on tamoxifen- 
containing chow. The only cells expressing Cre under these conditions 
are the hematopoietic cells, directly addressing the hematopoietic- 
intrinsic requirement. In both cases, long-term chimerism was com-
parable between groups, and isolation of donor cells from the BM and 
genomic PCR revealed homozygous deletion of Recql4 could not be 
maintained and was selected against, resulting in reconstitution by 
cells that had retained the floxed allele (Figure 6A).
tamoxifen-treated R26-CreERki/+Recql4+/+, R26-CreERki/+Recql4fl/+, 
and R26-CreERki/+Recql4fl/fl donors was performed (data not shown). 
This approach assesses the potential of the HSCs remaining after 
Recql4 deletion, but does not exclude a role for RECQL4 in regulating 
the supportive potential of the BM microenvironment. Surprisingly, 
PB chimerism was comparable among all genotypes (Supplemental 
Figure 5). Isolation of the donor-derived cells revealed a profound 
selection against cells deleted for Recql4, with retention of an un-
excised allele resulting in Recql4Δ/fl cells (Supplemental Figure 5). 
Similar negative selection phenotypes have been reported with 
floxed alleles for other genes with essential hematopoietic func-
tions, such as Tel, Mll, and Adar1 (35–37).
Figure 1. Somatic deletion of Recql4 causes anemia and leucopenia. (A) Schematic for the deletion strategy used in 7-week-old mice using R26-CreERT2 
and genomic PCR demonstrating deletion of Recql4 in BM. (B) Leukocyte counts in the PB of control (+/+) and Recql4 deficient (Δ/Δ) mice. (C) Absolute 
numbers of leukocyte subsets in PB. (D) Platelet count. (E) rbc count. (F) Hemoglobin. (G) Hematocrit. (H) images of BM flushes from the indicated geno-
types. (I) Representative histology of the tibia from epiphysis (region 1); trabecular region (arrowheads indicated adipocytes; region 2); and cortical region 
(region 3) of the bone. Scale bars: 50 μm; 20 μm (higher power image, region 3). Data expressed as mean ± SEM, Student’s t test. *P < 0.05; **P < 0.01. n ≥ 5 
per genotype. Experiments were independently performed on at least 3 separate cohorts, with results pooled for presentation.
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multilineage hematopoiesis and reconstitution by HSCs. Fur-
thermore, using 3 distinct HSC analysis methods, we demon-
strate very strong selection against deletion of Recql4.
Specific intrinsic requirements for Recql4 in B and T cell develop-
ment. To dissect B and T cell development in greater detail, we 
utilized an in vitro culture system. Lineage-negative, Sca-1–posi-
tive, c-Kit–positive (LKS+) cells were isolated from untreated R26-
CreERki/+Recql4+/+ and R26-CreERki/+Recql4fl/fl BM and placed into 
culture with tamoxifen for 5 days (Figure 7A). Cells were then 
transferred to differentiation cultures: an OP9 stromal cell layer 
for B cell development or OP9 cells expressing the Notch ligand 
delta-like 1 (OP9-DL1) for T cell development (40–42). Recql4Δ/Δ 
cells cultured under B cell conditions displayed a mild prolif-
erative disadvantage (data not shown) and recapitulated the im-
paired differentiation detected in vivo with impaired transition 
To corroborate the hematopoietic intrinsic function of Recql4 
we employed the hScl-CreERT strain, which allows specific gene 
deletion in the HSCs and primitive progenitors without the need 
for prior HSC transplant (37–39). hScl-CreERT R26-eYFPki/ki 
Recql4+/+, R26-eYFPki/kiRecql4fl/+, and R26-eYFPki/kiRecql4fl/fl were 
fed tamoxifen chow for 30 days to induce efficient gene dele-
tion in HSCs. hScl-CreERT R26-eYFPki/kiRecql4fl/fl did not present 
with a phenotype. At more than 5 months after tamoxifen ces-
sation, eYFP+ cells from the BM were isolated and gene deletion 
assessed. Consistent with previous results, we only detected 
stable deletion of a single floxed allele in eYFP-positive BM cells 
of the Recql4fl/fl mice (Figure 6B). Mice analyzed immediately fol-
lowing cessation of tamoxifen did not have any changes in con-
tribution to hematopoiesis of the eYFP-positive cells (Figure 6B). 
Transplant studies demonstrate that RECQL4 is essential for 
Figure 2. BM failure following deletion of Recql4. (A) BM cellularity per femur.(B) Numbers of granulocytes and macrophages per femur. (C) B lympho-
cyte number per femur and the indicated B cell subset. (D) Erythroid fractions based on CD71/Ter119 staining and representative FACS plots. (E) Erythroid 
fractions based on Ter119/CD44/FSC phenotype. (F) Analysis of cleaved caspase-3 staining in the BM. Scale bars: 100 μm (low power image); 50 μm (higher 
power image). Quantitation of percentage cleaved caspase-3 positive cells in each genotype from 3 hpf per sample, n = 3 per genotype. Data expressed as 
mean ± SEM, Student’s t test. *P < 0.05; **P < 0.001. n > 5 per genotype (A–E). Experiments were independently performed on at least 3 separate cohorts, 
with results pooled for presentation.
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esis was largely normal, with the exception of a mild reduction at the 
latest stages of differentiation (Figure 8, E and F). A modest, but not 
statistically significant, increase in the CD71+Ter119+ erythroblasts 
in the spleen was seen. In contrast to the negative selection using 
Rosa-Cre-ERT2 and Scl-CreERT (Figure 6), isolated eYFP-positive 
cells from the BM confirmed efficient Epor-Cre–mediated recombi-
nation of both alleles of Recql4 (Figure 8H). Therefore, RECQL4 is 
dispensable for the differentiation of committed erythroid cells.
Concurrent loss of p53 does not rescue RECQL4 deficient hemato-
poiesis. Given the extensive apoptosis and DNA damage observed in 
Recql4Δ/Δ BM, we tested whether concurrent p53 deletion would pro-
tect from these effects. p53 plays a critical role in cell cycle control and 
apoptosis phenotypes of both the Blm–/– and Wrn–/– mouse (45–47). 
In Fanconi anemia (FA), in which BLM helicase is implicated, knock-
down of p53 can rescue many hematopoietic phenotypes (48, 49). 
We generated R26-CreERki/+Recql4fl/+, R26-CreERki/+Recql4fl/fl, R26-
CreERki/+p53fl/fl, and R26-CreERki/+Recql4fl/flp53fl/fl (dKO) cohorts and 
placed all on tamoxifen chow for 30 days. Concurrent deletion of 
p53 was not able to rescue the hematopoietic phenotypes seen in 
Recql4Δ/Δ (Figure 9, A–H, and Supplemental Table 2). Loss of p53 does 
not modify the Recql4Δ/Δ BM failure, differentiating Recql4 from the 
closely related Blm in the regulation of hematopoiesis.
RecQ helicase–independent role for Recql4 in hematopoiesis. To 
determine to what extend loss of RECQL4 RecQ helicase activ-
ity or another function (such as Sld2-like replicative functions) is 
responsible for the hematopoietic defects, we tested the ability 
of GFP-fused human WT RECQL4 (RECQL4WT) or a RecQ heli-
from pre–proB to proB cells (Figure 7B and Supplemental Figure 
6). On OP9-DL1, Recql4 deficiency caused impairment at multiple 
stages, with total T cell output dramatically reduced. DN2b and 
DN3a subsets, phases where proliferation slows and stalls before 
β-selection, accumulated with a loss of more mature and prolifera-
tive T cell subsets. (Figure 7, C–E).
The differentiation stages affected by RECQL4 deficiency over-
lap closely with the peak expression of Recql4 transcript in B and 
T cells and temporally precede B and T cell receptor rearrangement, 
suggesting that the RECQL4 requirement is not linked to V(D)J re-
combination and DNA repair (Figure 7C). There were significantly 
increased levels in γH2A.X staining in Recql4Δ/Δ cultures during 
S-phase specifically and an accumulation of cells in S-phase (Fig-
ure 7, F–H, and Supplemental Figure 6C). Our data demonstrate 
that loss of RECQL4 results in increased replicative DNA damage, 
reminiscent of recent studies linking RECQL4 orthologues in other 
organisms to essential roles in DNA replication (12, 15, 16).
RECQL4 is dispensable for terminal erythroid differentiation. Dele-
tion of Recql4 using the R26-CreER model revealed a severe impact 
on erythroid progenitors that was not seen in the closely related my-
eloid progenitors (CMP and GMP, Figure 2). To determine whether 
there was an erythroid intrinsic requirement of RECQL4, indepen-
dent of the role in lineage commitment, we selectively deleted Recql4 
in erythroid progenitors using Epor-Cre (43, 44). Surprisingly we did 
not detect a difference in PB erythroid indices (Figure 8A). The dele-
tion efficiency was comparable between genotypes and the erythroid 
progenitor populations were similar (Figure 8, B–D). BM erythropoi-
Figure 3. Preservation of HSCs but depletion of erythroid progenitors following Recql4 loss. (A) HSC and primitive progenitors based on analysis of LKS 
CD34/Flt3 staining profiles. (B) Myeloid progenitor frequency and representative FACS profiles. (C) HSC and primitive progenitors based on analysis of 
LKS CD150/CD105 staining profiles. (D) Myeloid progenitors per femur. (E) Erythroid and megakaryocyte progenitor frequency in the BM and representa-
tive FACS plot. Data expressed as mean ± SEM, Student’s t test. n > 5 per genotype. Experiments were independently performed on at least 3 separate 
cohorts, with results pooled for presentation.
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case–dead variant (RECQL4K508A) to rescue Recql4Δ/Δ cells (11, 17). 
RECQL4K508A has an alanine substitution of the conserved lysine in 
the Walker A motif of the RecQ helicase domain that is essential 
for ATP hydrolysis (50–52). LKS+ cells were isolated from R26-
CreERki/+Recql4+/+ and R26-CreERki/+Recql4fl/fl and either placed di-
rectly into colony assays with 4-OHT or cultured and infected with 
retrovirus expressing WT or mutant GFP-RECQL4 (Figure 10A).
Deletion of Recql4 reduced colony formation from the LKS+ 
cells by approximately 70% compared with controls (Figure 10B). 
There was complete rescue of colony formation by LKS+ cells fol-
lowing the overexpression of RECQL4WT or RECQL4K508A and de-
letion of the endogenous Recql4 alleles (Figure 10C). Serving as an 
internal control, GFP–ve cells from the R26-CreERki/+Recql4fl/fl cul-
tures were not rescued. We also performed B and T cell cultures and 
Figure 4. Loss of RECQL4 compromises survival of the progenitor compartment. (A) Schematic for the deletion strategy used in 7-week-old mice and 
genomic PCR in BM after 14 days of tamoxifen. (B) Femur cellularity. (C) B lymphocyte number per femur and the indicated subsets. (D) Erythroid frac-
tions based on Ter119/CD44/FSC phenotype. (E) HSC and primitive progenitors based on analysis of LKS CD150/CD105. (F) HSC and primitive progenitors 
based on analysis of LKS CD34/Flt3. (G) Myeloid progenitor frequency and representative FACS profile. (H) Percentage dead (7AAD+AnnexinV+/–) of the 
LKS CD150/CD105 populations. (I) Percentage dead among erythroid progenitors in the BM. (J) Increased death of the proB and preB cell populations in the 
BM. (K) Analysis of death in the committed erythroid cells using Ter119/CD44/FSC fractionation. Fold difference appears below indicated P values. Data 
expressed as mean ± SEM, Student’s t test (Supplemental Table 1). *P < 0.05, **P < 0.01 or as indicated. n ≥ 3 per genotype.
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observed an outgrowth of GFP+ve cells from the Recql4Δ/Δ cultures 
with overexpression of either RECQL4WT or RECQL4K508A (Figure 
10D). Over 21 days of culture, the Recql4Δ/Δ cultures became almost 
completely composed of GFP+ve cells. When B and T cell differ-
entiation was assessed, rescue was found with both RECQL4WT 
and RECQL4K508A (Figure 10, E and F, and Supplemental Figure 7). 
Collectively, these studies demonstrate that the requirement for 
RECQL4 in hematopoiesis was RecQ helicase independent.
Discussion
The role of RECQL4 in vivo has been poorly characterized com-
pared with related RecQ helicases. The relative importance of its 
contribution to genome stability via its RecQ helicase domain and 
to DNA replication via its Sld2 homology region have not been de-
lineated. Our conditional Recql4 allele demonstrated an essential 
function for Recql4 in the maintenance of hematopoiesis. This phe-
notype was associated with widespread apoptosis of progenitor cells 
and increased replicative DNA damage. Recql4Δ/Δ HSCs were not 
transplantable, and there was profound selection for retention of 1 
unexcised allele. The requirement for RECQL4 was hematopoietic 
intrinsic and can be observed across B cell, T cell, and myeloid pro-
genitors. Using viral complementation of null cells, we established 
that the RecQ helicase function of RECQL4 is not required for its 
role in hematopoiesis. Therefore, the primary role of RECQL4 in 
hematopoiesis is as a participant in DNA replication rather than the 
regulation of genome stability. Consistent with this interpretation 
is the lack of mutations affecting the Sld2 homology regions in RTS 
patients, which would be expected to be nonviable based on our 
analysis (3, 6). Clarification of the function of RECQL4 is important 
for our understanding of RTS and the mutation spectrum that is ob-
served in patients. This should improve interpretation and analysis 
of sequence variants in people with a suspected RTS diagnosis.
The analysis of the conditional allele clarifies the previous am-
biguity related to the phenotype of Recql4 KO mice. Three germ-
line Recql4 alleles have been described. Homozygous loss of exons 
5–8 resulted in very early embryonic death (20), mirroring the 
early embryonic lethality of the germline deletion of exons 9–10 
reported with our KO allele (Supplemental Figure 1). An in-frame 
deletion of exon 13 caused a deficiency in helicase activity and 
was associated with neo- and postnatal lethality and other defects 
(19). A third mouse lacking exons 9–13 showed palate and limb de-
fects, aneuploidy, poikiloderma, and cancer predisposition (21). 
Interestingly, in the 2 lines where viable animals were recovered at 
birth, aberrantly truncated Recql4 transcripts can be found. Exon 
13 nulls expressed a transcript lacking exon 13, and several short-
ened truncated transcripts encompassing exons 1–12 can be ob-
served (19). Exon 9–13 KOs express 3′ truncated transcripts fusing 
exons 1–8 to the PGK cassette used to disrupt the gene (21). Thus, 
the viable hypomorphic alleles are able to generate an N-terminal 
fragment containing the Sld2 domain but lacking helicase activ-
ity, suggesting that the essential function of RECQL4 resides in its 
DNA replication function rather than its helicase activity. This is 
consistent with evidence from the analysis of cells engineered to 
express only the N-terminal region of RECQL4, which lacks the 
RecQ helicase domain. These cells had a normal basal prolifera-
tion rate but impaired DNA damage response. This demonstrated 
that expression of only the N-terminal, Sld2 homology region of 
RECQL4 protein is sufficient for normal proliferation (51).
Table 2. PB parameters after 14 days of tamoxifen food
PB Recql4+/+ mean 
(SEM)
Recql4Δ/Δ mean 
(SEM)
P value
wbc (×106/ml) 8.6 (1.2) 5.3 (1.2) <0.01
rbc (×109/ml) 9.9 (0.2) 9.1 (0.5) <0.05
Hct (l/l) 0.52 (0.01) 0.45 (0.01) <0.01
Hgb (g/l) 154.7 (4.6) 136.5 (5.0) <0.01
Hct, hematocrit; Hgh, hemoglobin.
Figure 5. Increased DNA damage and apoptosis of lymphoid cells following loss of Recql4. (A) Intracellular cleaved caspase-3 and γH2AX costaining  
B cell fractions of the BM. (B) Quantitation of cleaved caspase-3 and γH2AX in B cells as either the percentage or absolute number of positive cells per 
femur. (C) Total BM and thymus cleaved caspase-3 and γH2AX. Data expressed as mean ± SEM, Student’s t test. *P < 0.05. n ≥ 3 per genotype.
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described problems, and they survived much later in development 
than the Recql4–/– (55). Unlike Blm–/– animals, the concurrent loss 
of p53 had no effect on the outcome of deletion of Recql4 on the 
hematopoietic system (47). Recql5–/– are homozygous viable with-
out reported hematologic phenotypes, but develop tumors at long 
Comparison of conditional KO of Recql4 to that of other RecQ 
helicases revealed some striking differences in hematopoietic 
activity. Wrn–/– are not reported to have a hematological pheno-
type (53, 54). Blm–/– died at approximately E14.5 and had a distinct 
defect in erythropoiesis, including inclusion bodies but no other 
Figure 6. Profound selection against Recql4 deletion in HSCs. (A) Fetal liver or whole BM was isolated from donors of the indicated genotypes 
and transplanted into irradiated CD45.1 recipients. Hematopoiesis was allowed to establish for 5 weeks; then chimerism was assessed (4-week 
time point). Recipients were then placed on tamoxifen food for 30 days. PB was serially monitored at the indicated times, and total chimerism 
(CD45.2+ve) and myeloid chimerism (Mac-1+ve) are shown from each independent experiment. At end point, CD45.2 cells were isolated from the BM 
and genomic PCR performed to determine RECQL4 status;data shown are representative genotyping results from 1 of the experiments; n = 5 recipi-
ents/genotype/experiment. (B) hScl-CreERT R26eYFP Recql4 mice of the indicated genotypes were fed tamoxifen diet for 30 days. One cohort was 
left for long-term observation (upper panels). At end point, eYFP+ve cells were isolated from the BM and genomic PCR performed to assess Recql4 
status; the percentage of eYFP was assessed in the PB and BM. A second cohort was analyzed at the end of the 30-day feeding of tamoxifen. Femur 
cellularity, contribution of eYFP+ve cells to each phenotypic population, and genomic PCR were performed. n > 3 per genotype per experiment. Data 
expressed as mean ± SEM, Student’s t test. *P < 0.05.
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Figure 7. RECQL4 is intrinsically required for B and T cell development. (A) Outline of culture system to assess the requirement for RECQL4 in B and  
T cell development. (B) B cell development from the indicated genotype at 14 days after addition to the OP9 cultures. (C) Representative FACS plots from 
DN2 and DN3/4 T cell development at 14 days after addition to OP9-DL1 cells. (D) Quantitation of T cell development from DN1-DN4. (E) Analysis of DN2-4 
subset development following loss of Recql4. (F) Representative FACS plots of intracellular DNA damage (γH2AX) and DNA content. (G) Quantitation of 
cell-cycle distribution and DNA damage in T cell cultures at day 14. (H) Cell-cycle distribution and DNA damage in B cell cultures at day 14. Data expressed 
as mean ± SEM, Student’s t test. *P < 0.05; **P < 0.01. n = 4 per genotype. Experiments were independently performed on 2 separate occasions, with 
results pooled for presentation.
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lack of requirement for RECQL4. During polyploidization, there 
is a reduction in the expression of genes involved in DNA repli-
cation and repair, including known binding partners of RECQL4 
(59, 60). We assessed the expression of Recql4 in murine mega-
karyocytes via analysis of publicly available microarray data sets. 
In 2 independent data sets, Recql4 is below the detection thresh-
old in the megakaryocyte populations (60). We therefore propose 
that the main determinate of the lack of megakaryocyte/platelet 
phenotype in the Recql4Δ/Δ animals is the very low/negligible ex-
pression of RECQL4 during normal megakaryopoiesis.
Our preferred model is that the major determinant of the cel-
lular phenotype is the relative cell division rate of the respective 
populations (61). The increased division of committed progeni-
tors causes an increased rate of dilution of the RECQL4 protein 
present after recombination of the locus, to the critical point after 
which aberrant DNA replication occurs. The dilution model also 
hints at why we observed no requirement for RECQL4 in terminal 
erythroid differentiation using Epor-Cre. Erythroblasts undergo 
a limited number of cell divisions prior to enucleation (4 to 5 cell 
divisions from the proerythroblast stage), eliminating the need 
for further DNA replication (24, 62). Thus, viable erythroid cells 
latency (~50% of mice), with both hematologic and solid tumors 
represented (56). We therefore conclude that RECQL4 plays a 
nonredundant role with other RecQ helicases in hematopoieisis.
The requirement for RECQL4 in hematopoiesis is not uni-
form. The megakaryocyte lineage is preserved and platelet num-
bers in the PB remain unchanged. PB platelets have a normal 
morphology in RECQL4-deficient animals, and the numbers of 
megakaryocytes in the BM were comparable between controls 
and RECQL4-deficient animals (Recql4+/+ 6.2 ± 1.43 megakaryo-
cytes per high-power field (hpf); Recql4Δ/Δ 6.23 ± 1.30 megakaryo-
cytes/hpf; 10 hpf/tibia/animal assessed, n = 3 per genotype, data 
expressed as mean ± SEM). The other populations of cells that are 
spared consist of the HSCs and primitive progenitor populations, 
in contrast to the severely compromised committed progenitors. 
Recently, a population of phenotypic HSCs has been identified 
that possess a platelet-specific gene expression signature and dis-
play an ability at the single-cell level to directly differentiate into 
megakaryocytes and related myeloid lineages (57, 58). One ex-
planation could be that differentiation of committed progenitors 
from HSCs is impaired except toward the megakaryocytic pro-
genitors. Alternatively, megakaryocytes may be unique in their 
Figure 8. RECQL4 is dispensable for terminal erythroid differentiation. (A) PB parameters of erythroid-specific Epor-CreR26eYFPki/kiRecql4fl/+ and Epor-
CreR26eYFPki/kiRecql4fl/fl mutants. (B) Percentage eYFP-positive cells in each population for the indicated genotypes. (C) Numbers of erythroid progenitors 
per femur. (D) Numbers of myelo-erythroid progenitors per femur. (E) Erythroid fractions based on Ter119/CD44/FSC phenotype. (F) Erythroid fractions 
based on Ter119/CD71 phenotype. (G) Erythroid populations in the spleen. (H) Genomic PCR from eYFP+ve BM cells demonstrating efficient deletion of 
Recql4 using Epor-Cre. Data expressed as mean ± SEM, Student’s t test. n ≥ 4 per genotype.
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syndromes with clinical overlap with RTS, such as xeroderma pig-
mentosum, ataxia telangiectasia, FA, and dyskeratosis congenita. 
The RecQ helicase BLM interacts with the FA pathway (49, 66). 
However, the loss of RECQL4 resulted in a phenotype distinct from 
that associated with loss of Blm or reported in FA. Concurrent loss 
of p53 does not modify the Recql4Δ/Δ phenotype, whereas reduc-
ing the levels of p53 can normalize HSC function in FA cells (48). 
Additionally, at a cellular level, Recql4Δ/Δ cells display an S-phase 
accumulation, whereas FA cells accumulate intrastrand crosslinks 
and arrest in the G2/M phase of the cell cycle (66). One striking fea-
ture of the loss of RECQL4 function is the profound disruption to 
immune development. B cell differentiation is impaired from the 
pre-proB cell stage onward in the BM, and T cell development ap-
pears to be compromised by the loss of BM-derived thymic reseed-
ing cell populations. There are reports of immune compromise in 
patients with RTS (67, 68). The hematopoietic abnormality in 1 of 
these patients was corrected by an allogeneic cord blood stem cell 
transplant (68), confirming that, as in the mouse, this is a hemato-
poietic-intrinsic requirement for RECQL4. The range of severity of 
immune phenotypes and lineages affected in RTS patients may be 
reflective of retained function of the mutant RECQL4 protein.
The majority of mutations in RTS patients are located in 
the helicase domain of the protein and, most likely, given the 
early lethality of Recql4 null alleles, result in the expression of a 
C-terminal truncated hypomorphic RECQL4 protein with intact 
were found in the Epor-Cre Recql4Δ/Δ that had genomically deleted 
Recql4 but did not divide sufficiently after this point to dilute the 
remaining protein to a critical point. Consistent with this is that 
only the last stages of erythroid differentiation demonstrated any 
reduction. This model accounts for the apparent sparing of the 
primitive HSC fractions, as these populations are known to be 
relatively quiescent (61, 63). This explanation is consistent with 
recent evidence from the Xenopus midblastula transition, where 
it was shown that dilution of limiting RECQL4 protein levels re-
stricts the initiation of DNA replication (16). Thus, the in vivo phe-
notype is driven by the rates of dilution of RECQL4 protein after 
gene recombination, and the cells that divide most rapidly, such as 
the MPPs and committed progenitors, are most severely impacted 
by the absence of RECQL4. These results differentiate RECQL4 
from the other mammalian RecQ helicases and demonstrate a 
unique role for RECQL4 in the maintenance of hematopoiesis.
The phenotype of the Recql4Δ/Δ hematopoietic system, with the 
exception of the sparing of the megakaryocyte lineage, shares many 
of the key features of aplastic anemia in humans (64, 65). The genet-
ic causes of aplastic anemia are largely unknown, and the diagnosis 
is largely by exclusion. While it remains to be determined whether 
mutations in RECQL4 may contribute to the genesis of aplastic ane-
mia, the striking overlap of symptoms warrants further investiga-
tion of RECQL4 in these diseases. It may be warranted to assess the 
status of RECQL4 in patients with unexplained BM failure and in 
Figure 9. Concurrent p53 deletion does not modify the RECQL4 deficient pheno-
type. (A) Schematic of analysis of Recql4 p53 double mutants. (B) PB leukocyte 
and rbc counts. (C) BM cellularity. (D) HSC and MPP number per femur. (E) BM 
B cell populations. (F) BM erythroid populations based on CD71/Ter119 staining. 
(G) Thymus cellularity. (H) Thymic CD4/CD8 populations. There are no statistical 
differences between the R26-CreER Recql4Δ/Δ and R26-CreER Recql4Δ/Δp53Δ/Δ 
(dKO) for any of the parameters assessed at day 30 of analysis. Data expressed as 
mean ± SEM, ordinary 1-way ANOVA with multiple comparisons test. Statistical 
comparison only shown for Recql4Δ/Δ versus dKO. Full statistical analysis of all 
comparisons in Supplemental Table 2. n ≥ 4 per genotype.
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Figure 10. The RecQ DNA helicase function of RECQL4 is not required for hematopoiesis. (A) Outline of experimental design and constructs tested for 
rescue. (B) Genomic PCR from cells of each population treated for 5 days with tamoxifen, demonstrating efficient gene deletion, and CFU assays counted 
at day 7 from each population with tamoxifen added to the methylcellulose. (C) Analysis of the rescue of colony formation in cells of the indicated geno-
types infected either with WT or K508A helicase defective RECQL4; GFP–ve cells were included as a control. (D) Fold change in GFP levels and representa-
tive FACS plots relative to initial transduction levels over 21 days of culture for cells of the indicated genotypes. (E) B cell development is normalized by 
the K508A mutant. (F) Rescue of T cell development by helicase defective RECQL4. Data expressed as mean ± SEM, Student’s t test. n = 4 per genotype. 
Experiments were independently performed on 2 separate occasions with results pooled for presentation.
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Flow cytometric analysis of intracellular γH2AX (phospho-histone 
H2A.XSer139) and active caspase-3. 1–2 × 106 cells were stained for cell-
surface markers for 30 minutes at 4°C, washed once in PBS, then fixed 
and permeabilized for 20 minutes at room temperature (RT) using the 
BD Cytofix/Cytoperm (cat. No. 554714). Cells were pelleted, washed 
with BD Perm/Wash, and stained with biotin rabbit anti-active cas-
pase-3 antibody clone C92-605 (BD) in BD Perm/Wash buffer for 1 
hour at RT. Cells were next washed and resuspended in BD Perm/
Wash buffer containing Brilliant Violet 605 Streptavidin and Alexa 
Fluor 647 rabbit anti-γH2AX antibody clone 20E3 (Cell Signaling) for 
1 hour at RT, washed with BD Perm/Wash buffer, and resuspended in 
FACS buffer before analyzing by FACS. Results were analyzed with 
FlowJo Version 9.0 (TreeStar).
Flow cytometric analysis of intracellular γH2AX (phospho-histone 
H2A.XSer139) and cell cycle. T and B cell precursors were collected from 
the cocultures by filtration over 40 micron filters, washed with PBS, 
then fixed with 2% PFA for 20 minutes at RT. Cells were permeabi-
lized with ice-cold methanol for 30 minutes on ice, washed with PBS/
BSA, and resuspended in Alexa Fluor 647 rabbit anti-γH2AX antibody 
clone 20E3 (Cell Signaling) for 1 hour at RT. Cell were washed, resus-
pended in PBS containing 20 g/ml propidium iodide (PI) and 100 g/ml 
RNase A, and incubated for 1 hour before analyzing by flow cytometry. 
Results were analyzed with FlowJo software Version 9.0 (TreeStar). 
γH2AX foci were visualized on a per-cell basis using a laser scanning 
cytometer (Compucyte).
In vitro B and T cell assay. Cells were initially treated with 500 nM 
4-hydroxytamoxifen (4OH-T) (Merck) for 5 days to induce Cre activity 
and maintained in 100 nM of 4OH-T to enforce gene deletion. B cell 
cultures were performed in α-MEM (Sigma-Aldrich) with 20% FBS 
(PAA Gold), P/S, GlutaMAX, 5 × 10–5 M 2-mercaptoethanol (Sigma-
Aldrich), 5 ng/ml Flt3L (PeproTech), and 1 ng/ml mIL-7 (R&D Systems) 
and 100 nM 4-OH tamoxifen. B cell development was analyzed by flow 
cytometry on days 7, 14, and 21 (n = 4 separate donors/genotype). For 
T cell cultures, 20,000 OP9-DL1 cells (42) were plated in a 24-well plate 
48 hours before infected LKS+ cells were added. T cell cultures were per-
formed in α-MEM (Sigma-Aldrich) with 20% FBS (PAA Gold), P/S, Glu-
taMAX, 5 × 10–5 M 2-mercaptoethanol (Sigma-Aldrich), 5 ng/ml Flt3L 
(PeproTech), 0.25 ng/ml mIL-7 (R&D Systems), and 100 nM 4-OH 
tamoxifen (74, 75). T cell development was analyzed by flow cytometry 
on days 7, 14, and 21 (n = 4 separate donors/genotype).
Transplantation assays. Transplant configurations are outlined in 
the relevant figures. Transplants depicted in Figure 6A were performed 
once with fetal liver–derived cells and a second time with adult BM–
derived donor cells. For transplant of cells from tamoxifen-fed donors, 
5 × 105 unfractionated BM cells from R26-CreERT2ki/+Recql4+/+, R26-
CreERT2ki/+Recql4fl/+, or R26-CreERT2ki/+Recql4fl/fl were competitively 
transplanted with 2 × 105 WT BM cells (CD45.1/CD45.2). For transplant 
of non–tamoxifen-treated samples, either E14.5 fetal liver or adult BM 
of the indicated genotypes was isolated and transplanted into recipients. 
Recipients were allowed to recover for 4 weeks then assessed for chime-
rism. Recipients were placed on tamoxifen-containing food for 30 days, 
and then PB was analyzed at the indicated times. For all experiments, 
CD45.2+ve BM cells were isolated at end point to use for genomic PCR 
to assess Recql4 deletion.
All transplants were performed into lethally irradiated (2 × 5 Gy 
dose 3 hours apart; total of 10 Gy) recipients (CD45.1) through intra-
venous injections. All recipients received antibiotics for 3 weeks after 
Sld2-like function but absent/reduced helicase activity. Con-
sistent with a hypomorphic allele, Drosophila mutants of Recql4 
(RecQ4) have been isolated that are viable, display a range of 
phenotypes, and express only approximately 6% of the WT 
protein levels (69). The mutant protein is sufficient for DNA 
replication, but not for participation in DNA repair, potentially 
accounting for the aneuploidy reported in mice containing the 
C-terminal truncated alleles (21, 70, 71). The analysis of the con-
ditional allele has demonstrated that the essential in vivo func-
tion of Recql4 is in DNA replication rather than genome stability. 
This analysis allows a better understanding of the consequences 
of RECQL4 mutation and accounts for the prevalence of RTS 
mutations found within the helicase domain and their absence 
from the Sld2-like N-terminal region of RECQL4.
Methods
Mice. Recql4fl/fl mice (C57BL/6-Recql4tm2272Arte) were generated by 
TaconicArtemis GmbH. Full details of the allele are provided in the 
Supplemental Methods.
Rosa26-CreERT2 mice (22) on a C57BL/6 background were pur-
chased from The Jackson Laboratory and were used as heterozygotes 
for all experiments (B6.129-Gt[ROSA]26Sortm1(cre/ERT2)Tyj/J; stock num-
ber: 008463). Epor-Cre, p53fl/fl, R26eYFPki/ki and hScl-CreERT (provid-
ed by J. Göthert, University Hospital of Essen, Essen, Germany) have 
been previously described (37, 38, 43, 44, 72, 73). All lines were on a 
backcrossed C57BL/6 background.
Tamoxifen-containing food was prepared by Specialty Feeds at 
400 mg/kg tamoxifen citrate (Sigma-Aldrich) in a base of standard 
mouse chow.
Flow cytometry analysis. PB was analyzed on a hematological 
analyzer (Sysmex KX-21N; Roche Diagnostics). Bones were flushed, 
spleens crushed, and single-cell suspensions were prepared. Anti-
bodies against murine Ter119, CD71, B220, IgM, Mac-1, Gr1, F4/80, 
CD43, CD19, CD4, CD8, CD44, Sca-1, c-Kit, CD34, FLT3, FcγR 
(CD16/32), CD41, CD51, and CD150, either biotinylated or conju-
gated with FITC, phycoerythrin, phycoerythrin-Cy5, peridinin chlo-
rophyll protein–Cy5.5, phycoerythrin-Cy7, allophycocyanin, or allo-
phycocyanin Alexa Fluor 750 were all obtained from eBioscience. 
CD105 and CD150 were from BioLegend. Biotinylated antibodies 
were detected with streptavidin conjugated with Alexa Fluor 405 
or Brilliant Violet-605 (Invitrogen or BioLegend, respectively) (43). 
AnnexinV-APC (eBioscience) and 7-AAD (Molecular Probes) were 
used to assess viability as previously described (37). Cells were sorted 
on a BD FACSAria Cell Sorter (BD Biosciences) or analyzed on a BD 
LSRIIFortessa (BD Biosciences). Results were analyzed with FlowJo 
software version 9.0 (TreeStar).
Hematopoietic CFU assays. 50,000 whole BM cells, 300 LKS+ 
cells, 500 CMPs, or 1000 GMPs were plated per ml of methylcellu-
lose medium containing 50 ng/ml murine Stem Cell Factor (mSCF) 
(PeproTech), 10 ng/ml murine IL-3 (mIL-3) (PeproTech), 50 ng/ml 
human IL-6 (hIL-6) (Amgen), and 3 U/ml rhEpo (Jansen-Cilag). The 
methylcellulose medium used for colony assays contained 1% meth-
ylcellulose (Methocel MC no. 64630; Fluka), IMDM (Invitrogen), 
20% FBS for mouse myeloid CFC (Stem Cell Technologies), penicil-
lin/streptomycin (P/S) (Gibco; Invitrogen), GlutaMAX (Gibco; Invi-
trogen) and cytokines as described. Colonies were counted on day 7 
and day 12 as described (32, 43).
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transplant (Baytril). A total of 5 to 6 recipients per treatment were 
transplanted; the experiment was performed in duplicate. PB was 
taken at the indicated times to monitor multilineage donor reconsti-
tution and PB counts.
Retroviral complementation. Human EGFP-RECQL4 and EGFP-
RECQL4K508A (provided by T. Enomoto, Musashino University, Tokyo, 
Japan; ref. 17) were cloned into MSCV. All plasmids were sequence 
confirmed. Retrovirus was produced by transient transfection of 
293T cells using calcium phosphate precipitation. LKS+ cells were iso-
lated and cultured in StemSpan SFEM (Stem Cell Technologies) with 
20 ng/ml rhIL-6 (Amgen), 10 ng/ml rmIL-3 (Peprotech), 50 ng/ml 
rmSCF (Peprotech), and 5 ng/ml rhFlt3L (Peprotech) for 48 hours. 
Cells were then centrifuged with 50% (v/v) retroviral supernatant 
at 1100 g for 90 minutes in 8 μg/ml polybrene. Following infection, 
cells were cultured for a further 48 hours before being GFP sorted or 
used for in vitro culture.
Analysis of Recql4 expression in murine megakaryocytes. The expres-
sion of Recql4 in murine megakaryocytes was assessed via analysis of 
publicly available microarray data sets (GEO, NCBI). In 2 independent 
sets, Recql4 was below the detection threshold in the megakaryocyte 
populations (GEO GSE49664 and GSE6593).
Statistics. The significance of results was analyzed using the 
unpaired 2-tailed Student’s t test on the basis of highly inbred littermate 
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